Weight Management in Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Wharton, Sean ^a   Sharma, Arya M ^a   Lau, David C W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMFEPRAMONE; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; PHENTERMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

ABDOMINAL CRAMP; ABDOMINAL OBESITY; ABDOMINAL PAIN; AGE DISTRIBUTION; ARTICLE; BARIATRIC SURGERY; BLOATING; BODY MASS; CLINICAL PRACTICE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; ENERGY BALANCE; ETHNICITY; FECES INCONTINENCE; GASTRIC BANDING; GASTRIC SLEEVE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEALTH STATUS; HUMAN; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; METABOLIC REGULATION; MORTALITY; OBESITY; PATIENT ATTITUDE; PRACTICE GUIDELINE; QUALITY OF LIFE; SEX DIFFERENCE; SIDE EFFECT; STEATORRHEA; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION; BODY WEIGHT; CANADA; DIABETES COMPLICATIONS;

BARIATRIC SURGERY; BODY WEIGHT; CANADA; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; OBESITY; WEIGHT LOSS;

EID: 84876036454     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.025     Document Type: Article

References (67)

1. Wing R.R. Weight loss in the management of type 2 diabetes. Evidence-Based Diabetes Care 2000, 252-276. B.C. Decker, Inc, Ontario, Canada. H.C. Gerstein, B. Haynes (Eds.).
2. Conway B., Miller R.G., Costacou T., et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med 2010, 27:398-404.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
4. Ruderman N., Chisholm D., Pi-Sunyer X., et al. The metabolically obese, normal-weight individual revisited. Diabetes 1998, 47:699-713.
5. Markovic T.P., Jenkins A.B., Campbell L.V., et al. The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998, 21:687-694.
6. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
7. Stevens J., Cai J., Pamuk E.R., et al. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998, 338:1-7.
8. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096. Prospective Studies Collaboration.
9. Canadian Guidelines for Body Weight Classification in Adults 2003, Health Canada, Publication H49-179/2003E, Health Canada, Ottawa, ON.
10. Rabkin S.W., Chen Y., Leiter L., et al. Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group. CMAJ 1997, 157(suppl 1):S26-S31.
11. World Health Organization Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894:1-253. i-xii.
12. Reeder B.A., Senthilselvan A., Després J.P., et al. The association of cardiovascular disease risk factors with abdominal obesity in Canada. Canadian Heart Health Surveys Research Group. CMAJ 1997, 157(suppl 1):S39-S45.
13. Després J.P., Lemieux I., Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001, 322:716-720.
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
15. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. American Heart Association, National Heart, Lung, and Blood InstituteNational Heart, Lung, and Blood Institute.
16. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: IDF Communications; 2006. Available at:. Accessed September 1, 2008. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf.
17. Sharma A.M., Padwal R. Obesity is a sign-over-eating is a symptom: an aetiological framework for the assessment and management of obesity. Obes Rev 2010, 11:362-370.
18. Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes Spectrum 2007, 20:159-165.
19. Gorin A.A., Niemeier H.M., Hogan P., et al. Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the Look AHEAD trial. Arch Gen Psychiatry 2008, 65:1447-1455.
20. Ribisl P.M., Lang W., Jaramillo S.A., et al. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care 2007, 30:2679-2684.
21. Grunstein R.R., Stenlof K., Hedner J.A., et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007, 30:703-710.
22. Wing R.R., Marcus M.D., Epstein L.H., et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987, 10:563-566.
23. Dattilo A.M., Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
24. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
25. Elmer P.J., Grimm R., Laing B., et al. Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prev Med 1995, 24:378-388.
26. Tuomilehto J., Lindström J., Eriksson J.G., et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
27. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
28. Sumithran P., Prendergast L.A., Delbridge E., et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011, 365:1597-1604.
29. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998, 6(suppl 2):51S-209S.
30. Wing R.R. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010, 170:1566-1575. Look AHEAD Research Group.
31. Wadden T.A., West D.S., Neiberg R.H., et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity 2009, 17:713-722.
32. The American Diabetes Association's (ADA) evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care January 2012 vol. 35 no. Supplement 1.
33. Willett W.C., Dietz W.H., Colditz G.A. Guidelines for healthy weight. N Engl J Med 1999, 341:427-434.
34. Williamson D.F., Thompson T.J., Thun M., et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
35. Pavlou K.N., Krey S., Steffee W.P. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr 1989, 49(5 suppl):1115-1123.
36. Wing R.R., Hill J.O. Successful weight loss maintenance. Annu Rev Nutr 2001, 21:323-341.
37. Wing R.R., Goldstein M.G., Acton K.J., et al. Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care 2001, 24:117-123.
38. Rolls B.J., Morris E.L., Roe L.S. Portion size of food affects energy intake in normal-weight and overweight men and women. Am J Clin Nutr 2002, 76:1207-1213.
39. Rolls B.J., Roe L.S., Meengs J.S. Salad and satiety: energy density and portion size of a first-course salad affect energy intake at lunch. J Am Diet Assoc 2004, 104:1570-1576.
40. Wing R.R., Jeffery R.W. Outpatient treatments of obesity: a comparison of methodology and clinical results. Int J Obes 1979, 3:261-279.
41. Bennett G.A. Behaviour therapy for obesity: a quantitative review of the effects of selected treatment characteristics on outcome. Behav Ther 1986, 17:554-562.
42. Swinburn B.A., Walter L.G., Arroll B., et al. The green prescription study: a randomized controlled trial of written exercise advice provided by general practitioners. Am J Public Health 1998, 88:288-291.
43. Logsdon D.N., Lazaro C.M., Meier R.V. The feasibility of behavioral risk reduction in primary medical care. Am J Prev Med 1989, 5:249-256.
44. Campbell M.K., DeVellis B.M., Strecher V.J., et al. Improving dietary behavior: the effectiveness of tailored messages in primary care settings. Am J Public Health 1994, 84:783-787.
45. Lewis B.S., Lynch W.D. The effect of physician advice on exercise behavior. Prev Med 1993, 22:110-121.
46. Freedhoff Y., Sharma A.M. Best Weight: A Practical Guide to Office-Based Obesity Management 2010, Canadian Obesity Network, Canada.
47. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
48. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996, 276:1907-1915.
49. Scheen A.J., Lefèbvre P.J. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000, 16:114-124.
50. Finer N., Bloom S.R., Frost G.S., et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000, 2:105-112.
51. Heymsfield S.B., Segal K.R., Hauptman J., et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321-1326.
52. Lau D.C.W. Surgical options for patients with type 2 diabetes: a review of current and emerging therapies. Can Diabetes 2010, 23:3-13.
53. Abbatini F., Rizzello M., Casella G., et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc 2010, 24:1005-1010.
54. Mingrone G., Panunzi S., De Gaetano A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012, 366:1577-1585.
55. Schauer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366:1567-1576.
56. Reduction in the incidence of Type 2 diabetes with lifestyle or metformin. N Engl J Med 2002, 346:393-403. Diabetes Program Prevention Research Group.
57. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. ADOPT Study Group.
58. Rosenstock J., Hassaman D.R., Madder R.D., et al. Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized multicenter study. Diabetes Care 2004, 27:1265-1270.
59. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005, 7:73-82.
60. Rosenstock J., Schwartz S.L., Clark C.M., et al. Basal insulin therapy in patients with type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24:631-636.
61. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:541-549.
62. Coniff R., Sharpiro J., Robbins D., et al. Reduction of glycosylated haemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995, 18:831-843.
63. Hollander P., Pi Sunyer X., Coniff R. Acarbose in the treatment of type 1 diabetes. Diabetes Care 1997, 20:248-254.
64. Ahrén B., Landin-Olsson M., Jansson P.A., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2078-2084.
65. Scott R., Wu M., Sanchez M., Stein P. Efficacy and tolerability of the dipeptidylpeptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171-180.
66. Ratner R.E., Maggs D., Nielsen L.L., et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
67. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90. LEAD-2 Study Group.